Literature DB >> 3547468

Hepatobiliary complications of inflammatory bowel disease.

S M Williams, R K Harned.   

Abstract

A variety of biliary and hepatocellular diseases occur with increased incidence in patients with inflammatory bowel disease. These include fatty infiltration of the liver, cholelithiasis, pericholangitis-primary sclerosing cholangitis, cirrhosis, chronic active hepatitis, liver abscess, amyloidosis, granulomatous hepatitis, and bile duct carcinoma. Radiography is essential in accurate diagnosis.

Entities:  

Mesh：

Year:  1987        PMID： 3547468

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN： 0033-8389            Impact factor:   2.303


  5 in total

1.  Refractory ulcerative colitis accompanied with cytomegalovirus colitis and multiple liver abscesses: a case report.

Authors:  Takuya Inoue; Ichiro Hirata; Yutaro Egashira; Kumi Ishida; Ken Kawakami; Eijiro Morita; Naoko Murano; Shingo Yasumoto; Mitsuyuki Murano; Ken Toshina; Takashi Nishikawa; Norihiro Hamamoto; Ken Nakagawa; Ken-Ichi Katsu
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

2.  Experimental colitis in rats induces low-grade endotoxinemia without hepatobiliary abnormalities.

Authors:  H S Brand; M A Maas; A Bosma; R J Van Ketel; P Speelman; R A Chamuleau
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

Review 3.  Crohn's disease and the mycobacterioses: a review and comparison of two disease entities.

Authors:  R J Chiodini
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

Review 4.  Gut microbiota and inflammation.

Authors:  Asa Hakansson; Goran Molin
Journal:  Nutrients       Date:  2011-06-03       Impact factor: 5.717

5.  Combined hepatic and splenic abscesses in a patient with ulcerative colitis.

Authors:  Jeong Seon Ji; Hyung Keun Kim; Sung Soo Kim; Young Seok Cho; Hiun Suk Chae; Chang Wook Kim; Bo In Lee; Hwang Choi; Byung Wook Kim; Kyu Yong Choi
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.